Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leslie Hall

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Journal of Immunology (Baltimore, Md. : 1950)|October 8, 2005
Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344Carrie M Brodmerkel, Reid Huber, Maryanne Covington, et al.
Plos One|June 22, 2018
Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignanciesHolly Koblish, Yun-Long Li, Niu Shin, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 12, 2017
INCB040093 Is a Novel PI3K<i>δ</i> Inhibitor for the Treatment of B Cell Lymphoid MalignanciesNiu Shin, Yun-Long Li, Song Mei, et al.
ACS Medicinal Chemistry Letters|November 22, 2019
INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ)Eddy W Yue, Yun-Long Li, Brent Douty, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 30, 2020
Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase <i>δ</i> Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell MalignancyNiu Shin, Matthew Stubbs, Holly Koblish, et al.
Nature Communications|July 22, 2021
A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockadeCecile Geuijen, Paul Tacken, Liang-Chuan Wang, et al.
Human Molecular Genetics|November 18, 2008
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosisSergio E Baranzini, Joanne Wang, Rachel A Gibson, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Journal of Immunology (Baltimore, Md. : 1950)|October 8, 2005
Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344Carrie M Brodmerkel, Reid Huber, Maryanne Covington, et al.
Plos One|June 22, 2018
Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignanciesHolly Koblish, Yun-Long Li, Niu Shin, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 12, 2017
INCB040093 Is a Novel PI3K<i>δ</i> Inhibitor for the Treatment of B Cell Lymphoid MalignanciesNiu Shin, Yun-Long Li, Song Mei, et al.
ACS Medicinal Chemistry Letters|November 22, 2019
INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ)Eddy W Yue, Yun-Long Li, Brent Douty, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 30, 2020
Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase <i>δ</i> Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell MalignancyNiu Shin, Matthew Stubbs, Holly Koblish, et al.
Nature Communications|July 22, 2021
A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockadeCecile Geuijen, Paul Tacken, Liang-Chuan Wang, et al.
Human Molecular Genetics|November 18, 2008
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosisSergio E Baranzini, Joanne Wang, Rachel A Gibson, et al.
Pageof 4